Recent phase 1 clinical trials have highlighted the potential of TIM-3 blockade in the treatment of NSCLC, particularly in combination with PD-1/PD-L1 immune checkpoint inhibitors, to improve outcomes in different cancer types. This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.